HOUSTON , Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.  (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors and other cancers, today announced its chief executive officer, David Arthur ,

Conference Call and Live Audio Webcast Scheduled for Today, November 11, 2020, at 4:30 p.m. ET HOUSTON , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals , Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for children and adults with

Conference Call and Live Audio Webcast Scheduled for Wednesday, November 11, at 4:30 p.m. ET HOUSTON , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.  (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing treatments for pediatric cancers, solid tumors and other

HOUSTON , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC , a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive Officer, David Arthur, will present at the BIO Investor Forum Digital conference taking

Presentations Will Highlight Corporate and Clinical Progress HOUSTON , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced its participation at two upcoming

Webcast presentation scheduled for Tuesday, September 1, 2020 HOUSTON , Aug. 27, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc . (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive

Company Closes $6.2M Public Offering and Expands Clinical Program to Include Ewing-Related Sarcomas Conference Call and Live Audio Webcast Scheduled for Today, August 12, 2020 , at 4:30 p.m. ET HOUSTON , Aug. 12, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals , Inc. (Nasdaq: SLRX), a

Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET HOUSTON , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.  (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced that the

New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032 HOUSTON , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the

HOUSTON , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. . (Nasdaq: SLRX) today announced the closing of its previously announced underwritten public offering of 5,130,390 shares of its common stock, including 669,181 shares sold pursuant to the exercise in full of the